Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial

TEMPO 4:4 Trial Investigators

Research output: Contribution to journalArticlepeer-review

23 Scopus citations

Fingerprint Dive into the research topics of 'Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial'. Together they form a unique fingerprint.